Amanote Research
Register
Sign In
P1.01-98 a Phase IIIb Trial of Afatinib in EGFRm+ NSCLC: Analyses of Outcomes in Patients With Brain Metastases or Dose Reductions
Journal of Thoracic Oncology
- United States
doi 10.1016/j.jtho.2018.08.654
Full Text
Open PDF
Abstract
Available in
full text
Categories
Medicine
Oncology
Respiratory Medicine
Pulmonary
Date
October 1, 2018
Authors
Y. Wu
H. Tu
J. Feng
M. Shi
J. Zhao
Y. Wang
J. Chang
J. Wang
Y. Cheng
J. Zhu
E. Tan
K. Li
Y. Zhang
V. Lee
C. Yang
W. Su
D.C. Lam
B. Srinivasa
S. Rajappa
C. Ho
K.C. Lam
Y. Hu
S.A. Bondarde
X. Liu
D.C. Huang
Y. Wang
K. Pang
C. Zhou
Publisher
Elsevier BV
Related search
P1.01-92 a Phase II Study of Afatinib Treatment for Elderly Patients With Previously Untreated Advanced NSCLC Harboring EGFR Mutations
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P1.01-88 Osimertinib Maintenance After Definitive Chemoradiation in Patients With Unresectable EGFRm-Positive Stage III NSCLC (LAURA)
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P1.01-80 ELIOS: A Multicenter, Open-Label, Molecular Profiling Study of Patients With EGFRm and NSCLC Treated With Osimertinib
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P1.01-100 Concurrent Brain Radiotherapy and EGFR-TKI Have Better Survival Benefits in Patients With Brain Metastases From EGFR-Mutant NSCLC
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Phase I Clinical Trial Outcomes in 93 Patients With Brain Metastases: The MD Anderson Cancer Center Experience
Clinical Cancer Research
Cancer Research
Oncology
P1.01-60 Preventing and Treating Brain Metastases With Three First-Line EGFR-TKI in Patients With EGFR Mutation Advanced NSCLC
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
MA08.06 Outcomes Among Patients With EGFR-Mutant Metastatic NSCLC With and Without Brain Metastases
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
A Phase II Trial of Sunitinib in Patients With Renal Cell Cancer and Untreated Brain Metastases
Clinical Genitourinary Cancer
Oncology
Urology
MA08.01 Phase 3 Trial of Whole Brain Radiotherapy With Concurrent Erlotinib Versus WBRT Alone for NSCLC With Brain Metastases (ENTER)
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary